Navigation Links
Amicus Therapeutics Announces Second Quarter 2009 Financial Results
Date:8/5/2009

of Plicera pending the results of the ongoing Phase 2 trial.

AT2220 (1-deoxynojirimycin HCl) for the treatment of Pompe Disease

As previously reported, the Company suspended enrollment for the Phase 2 clinical trial of its investigational drug AT2220 for the treatment of Pompe Disease and received notice from the U.S. Food and Drug Administration (FDA) that the trial is on clinical hold.

The Company continues to work closely with the FDA to determine appropriate next steps for advancing the development of AT2220 and expects to provide guidance on this progress over the upcoming months.

Additionally, Amicus continues to be encouraged with its preclinical studies with AT2220 in combination with ERT. As previously announced, the Company expects to report additional data from these activities throughout the remainder of 2009.

Preclinical Chaperone Programs

Amicus continues to invest in research to assess the potential for applying its versatile chaperone technology platform to the treatment of a broad range of human genetic diseases. As part of this effort, Amicus continues to conduct preclinical studies in Parkinson's disease and is investing in new research aimed at evaluating disease targets for other neurodegenerative and genetic disorders.

Appointment of New Director

The Company announced today the election of James Barrett, Ph.D., to its Board of Directors. Dr. Barrett currently serves as General Partner of New Enterprise Associates (NEA), the Company's single largest shareholder, where he specializes in biotechnology and works with members of NEA's healthcare investment group on medical devices, healthcare information systems and healthcare services companies. Prior to joining NEA in 2001, Dr. Barrett served as Founder, Chairman and CEO of Sensors for Medicine and Science (1997 - 2001
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference
2. Amicus Therapeutics Announces Third Quarter 2007 Financial Results
3. Meredith Martin Addy Named Chair of AIPLAs Amicus Committee
4. Amicus Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference
5. Amicus Therapeutics to Host R&D Day
6. Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease
7. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
8. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
9. Amicus Therapeutics to Present at the BIO CEO & Investor Conference 2008
10. Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
11. Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... -- Scientists, including University of Oregon chemist Geraldine ... scaffolds of self-assembling, synthetic proteins called peptoid nanosheets ... The accomplishment -- detailed this week in a ... Proceedings of the National Academy of Sciences ... design of the two-dimensional peptoid nanosheets that can ...
(Date:9/2/2014)... Sept. 2, 2014  TransCelerate BioPharma Inc. ("TransCelerate") ... approach for protecting personal data in Clinical Study ... and others. The document describes an approach to ... CSRs and other related clinical trial documents, and ... goal of the TransCelerate CSR Redaction approach is ...
(Date:9/2/2014)... PA (PRWEB) September 02, 2014 ... a new highly efficient, cost effective approach to ... Patent No. 8,820,265 by the U.S. Patent and ... to Opertech. , “Opertech’s taste evaluation ... the first automated high throughput system for rapid ...
(Date:9/2/2014)... , Sept. 2, 2014 /PRNewswire/ - Oncothyreon Inc. (Nasdaq: ... M.D., President and Chief Executive Officer, will present at the ... in New York on Tuesday, Sept. ... live and archived webcast of the presentation will be accessible ... "News & Events" section. About Oncothyreon ...
Breaking Biology Technology:UO-Berkeley Lab unveil new nano-sized synthetic scaffolding technique 2TransCelerate BioPharma Inc. Releases Recommended Approach for Protecting Personal Data in Clinical Study Reports 2TransCelerate BioPharma Inc. Releases Recommended Approach for Protecting Personal Data in Clinical Study Reports 3Opertech Bio Receives U.S. Patent for High-Throughput Taste Evaluation Technology 2
... have created the first "active matrix" display using a ... toward realizing applications such as e-paper, flexible color monitors ... are made of "nanowires," tiny cylindrical structures that are ... The researchers used nanowires as small as 20 nanometers ...
... March 31 Chem Rx,Corporation (OTC Bulletin Board: ... services, announced today that it will hold a,conference ... 2008 outlook,on April 1, 2008 at 8:30 a.m. ... Steven C. Silva, President and Chief Operating,Officer, will ...
... ALTO, Calif., March 31 Varian, Inc.,(NasdaqGS: ... VF-5ht UltiMetal(TM),column for high temperature gas chromatography ... operating conditions. These highly durable columns,allow chemists ... temperatures, up,to 450 degrees Celsius. Based on ...
Cached Biology Technology:Engineers make first 'active matrix' display using nanowires 2Engineers make first 'active matrix' display using nanowires 3Chem Rx Corporation Schedules Conference Call to Review Full Year 2007 Financial Results 2New Capillary Column From Varian, Inc. Offers Durability and Performance for High Temperature GC and GC/MS 2
(Date:9/2/2014)... everyone has a tipping point. We all want to be ... is great enough. Now, scientists have confirmed the area of ... The result was published online this week in ... even if lying is beneficial," said Lusha Zhu, the study,s ... Tech Carilion Research Institute , where she works with Brooks ...
(Date:9/2/2014)... Sam Kean stops by Reactions this week to debunk ... that, despite what "Shark Week" may lead you to ... http://youtu.be/KhFygIoW_MA . , Kean,s book, "The Disappearing Spoon: ... History of the World from the Periodic Table of ... 10-episode video series produced for the newly launched American ...
(Date:9/2/2014)... for eating anything, including each other, camel crickets are ... Carolina State University finds that non-native camel cricket species ... , "The good news is that camel crickets don,t ... says Dr. Mary Jane Epps, a postdoctoral researcher at ... the research. , The research stems from a chance ...
Breaking Biology News(10 mins):Scientists find possible neurobiological basis for tradeoff between honesty, self-interest 2Scientists find possible neurobiological basis for tradeoff between honesty, self-interest 3Scientists find possible neurobiological basis for tradeoff between honesty, self-interest 4Researchers find Asian camel crickets now common in US homes 2
... State University and the University of Oxford are the ... how migrating birds use light and Earth,s weak magnetic ... 30, 2008, online issue of Nature that the photochemical ... weak magnetic fields similar to Earth,s when exposed to ...
... researchers have succeeded in wiping out established biofilms ... the bacteria,s own regulatory systems. Although the discovery ... offer insight into a dispersal mechanism for staph ... Biofilms are communities of bacteria that grow on ...
... the UN Conference on Climate Change (COP15) to be held ... to organise this conference as part of the run-up to ... try and capture some of the enormous research energy currently ... change. Thus, the focus of the conference is on providing ...
Cached Biology News:A model photochemical compass for bird navigation 2A model photochemical compass for bird navigation 3Turning on cell-cell communication wipes out staph biofilms 2Turning on cell-cell communication wipes out staph biofilms 3
Anti-human Carcinoma Associated Antigen, Clone 115D8, Monoclonal Antibody Innate Immunity - Tumor Markers...
Rabbit polyclonal to Survivin DEx3 ( Abpromise for all tested applications). entrezGeneID: 332 SwissProtID: O15392...
Anti-Mouse C-10, Biotin (Polyclonal) (rabbit IgG)...
Goat polyclonal to SART3 ( Abpromise for all tested applications). Antigen: Synthetic peptide: MSNADFAKLFLRK, corresponding to C terminal amino acids 951-963 of Human SART3 Entrez Gene ID: 9...
Biology Products: